Payment overview · 2025
General Payments
$1,230.49
44 reported records · 15 companies
Healthcare provider profile · identity verified
Marlene Cereceres
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · MIDLAND, TX · NPI 1649825001
Verified facts
What the public records show
CMS Open Payments records show Marlene Cereceres received $1,230.49 in general payments during 2025 across 44 reported records.
Novo Nordisk Inc accounted for 23.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $282.71 | 23.0% | 8 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $225.02 | 18.3% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $164.54 | 13.4% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $104.97 | 8.5% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $83.09 | 6.8% | 4 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $73.12 | 5.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $71.64 | 5.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $56.78 | 4.6% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.32 | 3.9% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $36.61 | 3.0% | 2 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $20.77 | 1.7% | 1 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $17.92 | 1.5% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.48 | 1.4% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.30 | 1.2% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $14.22 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,230.49 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $231.88 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $175.67 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $164.54 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $83.09 | 4 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $73.12 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $71.64 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $71.64 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $68.49 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $56.78 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $56.78 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $55.65 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $49.35 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $47.32 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $36.61 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $36.48 | 2 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $33.22 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 32 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 39 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
23 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
80 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
32 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 246 | 120 |
| Atorvastatin Calcium | Atorvastatin Calcium | 164 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 156 | 86 |
| Losartan Potassium | Losartan Potassium | 145 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 133 | 68 |
| Lisinopril | Lisinopril | 128 | 56 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 57 |
| Gabapentin | Gabapentin | 113 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 112 | 60 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 112 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 110 | 58 |
| Metformin Hcl Er | Metformin Hcl | 80 | 48 |
| Ozempic | Semaglutide | 80 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 33 |
| Furosemide | Furosemide | 60 | 28 |
| Liothyronine Sodium | Liothyronine Sodium | 54 | 30 |
| Metformin Hcl | Metformin Hcl | 53 | 28 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 52 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 28 |
| Montelukast Sodium | Montelukast Sodium | 48 | 26 |
| Carvedilol | Carvedilol | 47 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 25 |
| Tramadol Hcl | Tramadol Hcl | 43 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 31 |
| Tresiba Flextouch U-200 | Insulin Degludec | 40 | 18 |
| Mounjaro | Tirzepatide | 39 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 38 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 22 |
| Meloxicam | Meloxicam | 36 | 23 |
| Methylprednisolone | Methylprednisolone | 36 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 19 |
| Donepezil Hcl | Donepezil Hcl | 34 | 17 |
| Omeprazole | Omeprazole | 33 | 15 |
| Sertraline Hcl | Sertraline Hcl | 33 | 18 |
| Eliquis | Apixaban | 32 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 23 |
| Azithromycin | Azithromycin | 29 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 26 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 29 | 17 |
| Alendronate Sodium | Alendronate Sodium | 27 | 15 |
| Alprazolam | Alprazolam | 26 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Potassium Chloride | Potassium Chloride | 24 | 18 |
| Jardiance | Empagliflozin | 23 | 12 |
| Allopurinol | Allopurinol | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | 15 |
| Glimepiride | Glimepiride | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | 13 |
| Celecoxib | Celecoxib | 19 | 11 |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Ezetimibe | Ezetimibe | 18 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 12 |
| Famotidine | Famotidine | 15 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Indapamide | Indapamide | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | 11 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Bumetanide | Bumetanide | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Simvastatin | Simvastatin | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,230.49 · 44 records | Novo Nordisk Inc | COLLAGENASE SANTYL, ELIQUIS, FREESTYLE LIBRE, FREESTYLE LIBRE 3, Flector, GVOKE HYPOPEN, Licart, MOUNJARO, NEXLETOL, NURTEC ODT, NUZYRA, OTEZLA, PANCREAZE, QULIPTA, REPATHA, Tirosint, UBRELVY, VRAYLAR, VYEPTI, Veozah, Wegovy, XHANCE, ZENPEP, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error